Eyenovia to Participate in Multiple Medical Meetings in September

NEW YORK, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic pharmaceutical technology company developing a pipeline of late-stage microdose array print (MAP™) therapeutics, today announced that the company will be participating in multiple medical meetings in September. Details of the presentations are as follows:

Meeting: Ophthalmology Futures European Forum 2022Title: The Optejet – Advancing Drug Delivery and Improving Patient ExperiencePresenter: Beth Scott, OD, VP, Regulatory and Medical AffairsDate: Thursday, September 15, 2022Location: Principe di Savoia, Milan, Italy

Meeting: The T.H.E. Summit by Treehouse EyesTitle: Drug/Device Technology to Improve Pediatric Progressive Myopia TreatmentPresenter: Michael Rowe, Chief Executive OfficerDate: September 15, 2022Location: Caesars, Las Vegas, NV

Meeting: 40th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS) 2022Title: In Vitro Cell Toxicity Comparing Microdose vs Drop Delivery of Latanoprost with BAK in Human Conjunctival CellsPresenter: Pedram Hamrah, MD, FACS, Department of Ophthalmology, Tufts Medical CenterDate: September 16-20, 2022Format: ePoster presentation, accessible for the duration of the conferenceLocation: Milano Convention Centre, Milan, Italy

Meeting: Eyecelerator at AAO 2022Title: The Optejet® | The First and Only Human-Centric Ophthalmic Topical Medication DevicePresenter: Michael Rowe, Chief Executive OfficerDate: Thursday, September 29, 2022Location: McCormick Place, Chicago, Il

About Eyenovia, Inc.Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAPTM) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com.

The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations.

Forward-Looking StatementsExcept for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. Forward-looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictions or any other statements relating to our future activities or other future events or conditions, including estimated market opportunities for our product candidates and platform technology. These statements are based on current expectations, estimates and projections about our business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and in some cases are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors discussed from time to time in documents which we file with the U.S. Securities and Exchange Commission. In addition, such statements could be affected by risks and uncertainties related to, among other things: risks of our clinical trials, including, but not limited to, the costs, design, initiation and enrollment (which could still be adversely impacted by COVID-19 and resulting social distancing), timing, progress and results of such trials; the timing of, and our ability to submit applications for, obtaining and maintaining regulatory approvals for our product candidates; the potential impacts of COVID-19 on our supply chain; the potential advantages of our product candidates and platform technology; the rate and degree of market acceptance and clinical utility of our product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties to develop and commercialize our product candidates; the ability of us and our partners to timely develop, implement and maintain manufacturing, commercialization and marketing capabilities and strategies for our product candidates; intellectual property risks; changes in legal, regulatory and legislative environments in the markets in which we operate and the impact of these changes on our ability to obtain regulatory approval for our products; and our competitive position. Any forward-looking statements speak only as of the date on which they are made, and except as may be required under applicable securities laws, Eyenovia does not undertake any obligation to update any forward-looking statements.

Eyenovia Contact:Eyenovia, Inc.John GandolfoChief Financial Officer[email protected]

Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLC[email protected](646) 751-4363

Eyenovia Media Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operations[email protected]

You May Also Be Interested In

• CDR-Life to Present Tumor Targeting Capabilities of M-gager® Platform at the TCR-Based Therapies for Solid Tumors Summit
• RESULT OF RIKSBANK CERTIFICATE SALE
• Recording of LHV Group's 23 April investor webinar